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15.1 Introduction
Introduction and use of a health technology in a health care setting has clinical, eco-
nomic, as well as organizational, social-cultural, legal and ethical impacts. Health Tech-
nology Assessment (HTA) is a multidisciplinary ield that addresses these impacts, con-
sidering the healthcare context as well as available alternatives. HTA mainly aims to 
inform policy and clinical decision making. While systematically evaluating the efects of 
the health technology, HTA addresses direct and intended efects as well as the indirect 
and unintended efects. It is a multidisciplinary ield with well-developed systematic pro-
cesses and methods [1,2].
A health technology is deined as an intervention that may be used to promote health, 
to prevent, diagnose or treat acute or chronic disease, or for rehabilitation. Health tech-
nologies include pharmaceuticals, devices, diagnostics, procedures and other clinical, 
public health and organizational interventions [1,2].
Before a health technology is provided to the right patient, who could beneit from it 
at an afordable price, traditionally several hurdles are faced: the eicacy and safety of a 
health technology need to be proven; and must be produced with a high quality. hese 
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three are necessary for marketing authorization. he fourth hurdle, being assessed for 
cost-efectiveness, is often a payer’s requirement for reimbursement. HTA is mostly done 
or requested by relevant authorities to assess how the new product compares with the 
current alternatives and whether it adds value. Perhaps a decade ago, the distinction was 
more straightforward and the fourth hurdle was separated from the irst three. But to-
day the processes are more integrated and redesigned to provide earlier access to valu-
able technologies.
Health authorities across countries, including western countries, are inding it in-
creasingly di cult to fund all new premium priced medicines [3]. he situation is exac-
erbated by changing demographics, increasing prevalence of chronic diseases especially 
non-communicable diseases, the continued launch of new premium priced medicines to 
address existing unmet need adding to therapeutic complexities, alongside population 
fragmentation with increasing knowledge of pharmacogenomics, as well as rising patient 
expectations [4-6].
In this chapter, we aim to explore HTA’s role in market access with speciic examples 
from diferent countries. In line with the scope of the book, we will focus on the pharma-
ceuticals and developed markets only. We will outline how HTA might lead to diferent 
outcomes in diferent settings and cover new possibilities and challenges to be addressed.
15.2 History of HTA
A healthy society plays a key role in the development of a country and this makes 
health services one of the most important indicators of a countries’ development level 
[7,8]. he fundamental purpose of healthcare services is to provide the public with equal 
access to high quality and timely services at a sustainable cost [4,8]. he organization of 
healthcare and funding systems difer according to the socioeconomic conditions and po-
litical context of the relevant country [5,9].
As countries develop economically, health technologies advance rapidly. Rapid devel-
opments increase the demand for health care services, and consequently health expendi-
ture dynamics increase [9].
he rapid difusion of health technologies challenges governments to provide high 
quality, equal and accessible care for the citizens while managing the health care budgets 
efectively. Questions about the efectiveness of experimental technologies, as well as in-
creased health care expenditures and restricted health care budgets, led to the develop-
ment of HTA [10].
Health Technology Assessment became a concept in 1976; it initially spread from 
the United States (U.S.) to Western Europe and in recent years HTA is rapidly develop-
ing worldwide. In 1967, HTA was irst used as a term in United States Congress [11]. 
In 1972, the U.S. Congressional Oice of Technology Assessment (OTA) was estab-
lished and OTA initiated a health program in 1974. During this program OTA pub-
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lished eighty diferent HTA reports [12], especially focusing on eicacy, safety, and 
cost-efectiveness [13]. he early products of OTA and evidence based reviews derived 
by the Cochrane Collaboration displayed the most important roles on shaping the ield 
of HTA.
Inspired by the reports of OTA, he Swedish Council on Technology Assessment in 
Health Care (SBU) started HTA development in Europe [13]. his irst period of syn-
thesizing the available evidence with eicacy and cost-efectiveness supported poli-
cy-makers in national health programmes with regard to evidence-informed decision-
making [11]. After 1985, HTA has gradually spread to nearly all western and southern 
European countries, then to Central Europe, Latin America, and Asia. International or-
ganizations such as the World Bank, World Health Organization (WHO), International 
Society of Technology Assessment in Health Care (ISTAHC), its successor Health Tech-
nology Assessment International (HTAi), and the International Network of Agencies 
for Health Technology Assessment (INAHTA) all beneit the development and use of 
HTA [13].
15.3 HTA and Market Access
Market access is deined as “openness of a country’s markets to foreign goods and 
services” [14]. Although this is the basic deinition, pharmaceutical market access can 
be considered as a longer and comprehensive process. his is a challenging process 
where many stakeholders are involved. Processes such as HTA, pricing and reimburse-
ment; industry processes such as R&D, registration, marketing authorization and 
launch might impact the access process [15]. Furthermore, although there are com-
mon frameworks to demonstrate the quality, safety and eicacy of a product, there re-
mains fragmentation regarding marketing authorization applications across the coun-
tries in Europe [5].
Due to inancial crisis or economic concerns, governments face di cult times and pri-
orities need increasingly to be set given the extent of unmet need that still exists [4,16]. 
Especially, the last decade has witnessed cost-cuts and increased price negotiations and 
in this context, HTA has been increasingly recognized to meet policymakers’ needs by 
providing them information on the costs and beneits of drugs. Although the focus lies 
on providing value for money, it has been quite hard to measure value, interpret it and 
have data on the appropriate impact on the outcome [17].
HTA serves the purpose of providing policymakers with reliable assessments of the 
pharmaceuticals that would relect the real world, but also will aid the manufacturers to 
prove the value of the drugs they have produced. HTA might highlight the drugs that are 
expensive compared to their beneits, or might outline the indications and patient groups 
that would have additional value. Unsafe and inefective drugs will also be discovered 
during these processes, leading to active dissemination [18-20].
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15.4 HTA, Regulation, Pricing and 
Reimbursement of Pharmaceuticals
It is relatively easier to harmonize regulatory processes across countries, while pric-
ing and reimbursement decisions on pharmaceuticals depend more on the local con-
text [4,5,21]. For example, it is very di cult to translate cost-efectiveness from one 
setting to another. Furthermore, the political and health care context, national/re-
gional priorities and social values difer across countries, making it more complex to 
transfer the outcomes of HTA evaluations. his is quite challenging for the manufac-
turers as they need to understand expectations of HTA organizations which may vary 
from country to country. To address this, for instance European countries are seeking 
to collaborate on HTA assessments (EUnetHTA – discussed later) as well as trying to 
ind ways to collaborate on methodology development and approaches regarding ear-
lier access to medicines including adaptive pathways, and several stakeholders are in-
volved in this collaboration. he approaches will further be explored later in this chap-
ter.
In many countries, pricing and reimbursement decisions are taken at the national lev-
el. he manufacturer needs to submit a dossier for this purpose after obtaining market-
ing authorization; i.e. a license issued by a medicines agency approving a medicine for 
market use based on a determination by authorities that the medicine meets agreed re-
quirements of quality, safety and eicacy for human use in therapeutic treatment [5]. 
Many countries use HTA to subsequently guide or inform the pricing and reimbursement 
processes by assessing the drug’s beneits compared to its alternatives alongside cost con-
siderations [21]. In addition to clinical and economic aspects, increasingly other aspects 
related to the use of a particular medicine are considered. In certain cases, such as life-
threatening conditions or orphan diseases, the assessment might ind limited evidence 
or low cost-efectiveness, but the (unmet) need might be high as there are limited ther-
apeutic alternatives. In this case, HTA can be used as a tool to support prioritization en-
suring a more rational investment of funds, based on social needs and policy priorities 
[22]. HTA seems to be the preferred strategy as it addresses both price and appropriate 
indications for the use of the medicine and the relation between additional value and ad-
ditional costs [4,22,23].
HTA might inform policymakers about diferent options and scenarios where there is 
more lexibility on pricing and reimbursement policies. Rather than an absolute yes or 
no to reimbursement, companies might need to bring in more evidence to showing bene-
it on certain conditions. he increasing number of high-priced drugs has started to chal-
lenge even wealthier countries to develop policies on how to improve access to medicines 
in an afordable way. Europe, for example, has set this issue high on their agenda [4,24]. 
his led to innovative ways of pricing and reimbursing pharmaceuticals, such as value 
based pricing or managed entry agreements [4,5,25]. hese approaches, especially man-
aged entry agreements, were created to enable access to (coverage/reimbursement of) a 
product subject to speciied conditions, such as price negotiations. While this is a way 
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to provide access to the drug, it risks transparency and transferability at the global level 
[4,25]. We will discuss this further in this chapter.
he European Commission has inancially supported several HTA projects to promote 
the collaboration between Member States (MS) in the European Union (EU) since 1993 
[4]. he European Commission and Council of Ministers designated HTA as “a political 
priority” in 2004, recognizing «[…] an urgent need for establishing a sustainable Euro-
pean network on HTA» [26]. EUnetHTA has coordinated these activities since 2006. EU-
netHTA is deined as a «network of government appointed organizations [from EU MS, 
EU-accession countries, plus European Economic Area (EEA) and European Free Trade 
Association (EFTA) countries] and a large number of relevant regional agencies and non-
for-proit organizations that produce or contribute to HTA in Europe». he collaboration 
has already resulted in methodological guidelines and tools such as the HTA Core Model 
– a methodological framework for shared production and use of HTA information in the 
era of diagnostic technologies, medical and surgical interventions, drugs and screening 
technologies. he purpose is «to enable production of high quality HTA information in a 
structured format to support the production of local (national or regional) HTAs and re-
use of existing information». HTA organizations use this model as the value framework 
when assessing technologies within the EU [27].
Since 2009, EUnetHTA collaborated with the European Union and the European Com-
mission partners to administer joint assessments and implement the results. EUnetH-
TA has inished 20 joint assessments until 2015. his cooperation on HTA projects has 
the potential to increase the quality of HTA. An assessment can be done in two diferent 
ways; a rapid Relative Efectiveness Assessment (REA) and a full HTA. We can evaluate 
the incremental therapeutic value of technologies with a rapid REA; however, a full HTA 
has a broader perspective. A rapid REA covers the following domains: health problem and 
current use of technology, description and technical characteristics, safety and clinical ef-
fectiveness; furthermore, a full HTA also includes the following domains: costs and eco-
nomic evaluation, ethical analysis, organizational aspects, patient and social aspects, and 
legal aspects [27].
Relative efectiveness is deined as «the extent to which an intervention does more 
good than harm compared with one or more alternative interventions under the usu-
al circumstances of healthcare practice». Especially payers are more interested in eval-
uating the relative efectiveness of new healthcare technologies compared to standard 
care or other technologies, and have documented their preferred comparators [21]. his 
interest in relative efectiveness information in Europe is due to the early information 
need for guiding reimbursement and funding decisions about new health technologies 
[3-5,28].
EUnetHTA published a review about REA in 2011. According to this report, most 
countries surveyed use REA to support national reimbursement decisions of drugs, but 
the subject and methodology vary across countries due to the health system, reimburse-
ment processes, the socio-cultural structure and the level of GDP per capita of the coun-
try [27].
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15.5 How HTA Differs from One Setting to Another
he scope and methods of HTA may be adapted to the needs of a particular health sys-
tem, but it is known that each country has its own priorities, sources and unique deci-
sion-making processes. Below we will give four country examples on how HTA structures 
change from setting to setting and discuss how they compare with regard to the decisions 
made with certain pharmaceuticals.
HTA in France
In France, HTA is governed and organized oicially based on the legislations of the 
government and the SHI (Statutory Health Insurance or Assurance Maladie in French) 
[29]. he French government established the main French HTA organization, called HAS 
(French National Health Authority or Haute Autorité de Santé in French) in August 2004 
[29,30]. he main goal of the HAS was determined as being the single organization which 
covers many activities aiming to improve the quality of health care and ensure equity 
within the health system [30]. In order to achieve this goal, this organization assesses 
drugs, reagents, tests, medical devices, practices and procedures as well as health pro-
grammes; develops guidelines; provides training and information about quality; accredi-
tates health care providers and certiies physicians [29,30]. As an independent (non-gov-
ernmental) public institution, HAS has inancial autonomy and collaborates with several 
partners such as governmental health agencies, national health insurance funds, research 
centres, societies of healthcare professionals and patients [30].
HAS has extensive in-house scientiic expertise, nevertheless it is also authorized 
to undertake commissions external experts (e.g. academicians, professionals, other ex-
perts) [29,30]. HTA is done by the HAS before inclusion of new medicines on the positive 
list for reimbursement can occur [29]. After a health technology receives the regulatory 
approval from EMA (European Medicines Agency) or AFSSAPS (French Health Products 
Safety Agency or Agence Française de Sécurité Sanitaire des Produits de Santé in French), 
an HTA report is an obligation in order to be considered for pricing and reimbursement 
by French decision makers [29,30]. Necessary HTA is conducted by two speciic commis-
sions within the HAS [29]. he Transparency Commission (Commission de la Transpar-
ence in French) evaluates drugs, while CNEDIMTS (National Commission for the Evalua-
tion of Medical Devices or Commission nationale d’évaluation des dispositifs médicaux et des 
technologies de santé in French) evaluates medical devices and procedures [29]. Obligato-
ry HTAs, which are done for all new health technologies by the aforementioned commis-
sions based on the documents presented by the manufacturers before the market launch, 
have a direct inluence on the reimbursement rate of SHI and a less direct inluence on 
the price (statutory tarif) [29,30]. Two reviewers evaluate and criticize each HTA study, 
before it is discussed by the relevant commission. he HTA procedure in France may be 
classiied into two steps [29,30]:
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t First step is the assessment of the product’s medical beneit or therapeutic value 
which is called SMR (Service Medical Rendu in French) [21,29,30]. his assessment 
is done in absolute terms for all diferent types of use of the product, based on its 
clinical eicacy and safety, its importance within the therapeutic strategy, existence 
or absence of its alternatives, severity of disease which is indicated to treat, type of 
the treatment (preventive, curative or symptomatic) and its impact on public health 
which relects epidemiological issues and quality of life [29,30]. he SMR level of the 
health technologies (e.g. major or considerable, important, moderate, low or weak 
but justifying reimbursement, insuicient) play an important role with reimburse-
ment decisions and the reimbursement rate (from 0 to 100%) decisions [29,30].
t he second step is the assessment of the product’s relative medical beneit compared 
to similar alternatives which is called ASMR (Improvement in the Relative Medical 
Beneit or Amélioration du Service Medical Rendu in French) for drugs or ASA (Im-
provement in Expected Beneit or Amelioration du Service Attendu in French) for med-
ical devices and procedures [21,29,30]. his assessment is done and a grade, based on 
the improvement in medical efectiveness over similar alternatives, is given by the 
Transparency Commission for drugs and CNEDIMTS for medical devices and pro-
cedures [29]. ASMR or ASA grades of the health technologies (e.g. 1 for “major im-
provement” or “life-saving health technology”, 2 for “important improvement”, 3 for 
“signiicant or moderate improvement”, 4 for “minor improvement”, 5 for “no im-
provement”) afect the decisions on pricing explicitly [21,29,30]. herefore, this step 
of the assessment incentivizes the manufacturers to provide suicient data about 
their products [29].
he HAS commissions examine the documents of the manufacturers, reviews the ex-
isting literature systematically and eventually updates all previous decisions about exist-
ing health technologies once every ive years [29].
Since 2013, another HAS commission called CEESP (Commission for Economic Eval-
uation and Public Health or Commission d’Évaluation Économique et de Santé Publique in 
French) conducts an economic assessment under speciic conditions such as; having a 
health technology which is considered as ASMR/ASA grade 1, 2 or 3 and may inluence 
SHI expenditure signiicantly by its price and/or its efect on health care services’ organi-
zation, medical practices or coverage conditions of patients or having a health technolo-
gy which have or is expected to have a 20 million Euros or higher turnover after two years 
on the market [29].
he Ministry of Health is the responsible body to commission the assessment of other 
technologies such as the necessary equipment for a procedure [29]. Waiting until any ad-
ditional information becomes available, or asking for surveys or observational research, 
are possible advices which follow the HTA reports [29]. It is usual that the manufactur-
ers inance the research [29]. However, the researchers should be independent from the 
inanciers [29].
here are multiple criteria used in the appraisal process that is done by the Transparen-
cy Commission. he most important criteria for the opinion are actual beneit, improve-
ment in actual beneit, and target population. here is a formal appeal process of 90 days 
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in which companies get the chance to appeal and contest the decision. he HAS makes 
a recommendation to UNCAM (National Union of Health Insurance Funds or Union Na-
tionale des Caisses d’Assurance Maladie in French), which provides the Ministry of Health 
with a inal recommendation about inclusion in the SHI [31].
HTA in the Netherlands
he health system of the Netherlands includes a social health insurance system in 
which public insurance is compulsory. Citizens older than 18 years pay a lat premium 
per year for the basic insurance, while people with low incomes are inancially compensat-
ed. In addition, complementary (voluntary) insurance exists. hrough the Health Insur-
ance Act, citizens are entitled to a basic beneit package, although for some entitlements 
co-payments exist. Health insurers play an important role in implementing the Health 
Insurance Act, and they are obliged to accept each citizen that wants to pursue a health 
insurance with them [32].
In 2016, around 10% of GDP was spent on health care, while this was around 9% in 
2007. he Health Insurance Act governs curative care, including primary care and hospi-
tal care. Around 60% of the health care budget (700 million Euros in 2016) is allocated to 
this part of health care [32,33].
he Ministry of Health, Welfare and Sports (VWS) is responsible for the content of the 
beneit package, which comprises essential medical care, medical aids as well as pharma-
ceuticals. he National Health Care Institute (ZIN) also plays an important role – it has a 
legal advisory task with regard to the beneit package; its Appraisal Committee (ACP) has 
an advisory role in coverage-decision-making, while the Ministry of Health makes the i-
nal decision.
HTA has been introduced in the Netherlands in the early 1980s. At that time, the 
Health Insurance Council (now ZIN) and the Ministry of Health became concerned about 
the rapid developments in health technology (e.g. transplantations, and IVF) and their 
impact on health care and society, especially in terms of cost. During the 1980s and the 
1990s, a series of policy-oriented reports were published that either focused on HTA or 
included HTA as part of future policy in the Netherlands. All these reports recommend-
ed a strong program of HTA as part of Dutch health care. An important impetus for HTA 
in the Netherlands was the launch of a national HTA research program in 1988 [34]. he 
Ministry of Health funds the program, which is currently running for the years 2016-
2018 and 2019-2021 [35]. he program has evolved over the years, from being a more ac-
ademic program, towards a program that is addressing the needs of health care profes-
sionals, patients and decision-makers [36]. In 1991, the Committee on Choices in Health 
Care (Commissie Dunning) suggested to use HTA for coverage decision-making using four 
criteria: necessity, efectiveness, eiciency and whether or not the interventions can i-
nancial borne by the individual (afordability) [34]. Since 2006, the main role of ZIN is 
managing the beneit package of health care, and one of its tasks is to advice the Min-
ister of Health about coverage decision-making. ZIN currently makes use of four crite-
ria, clearly inspired by those set out by the Dunning Committee: necessity, efectiveness, 
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cost-efectiveness and feasibility. Franken et al [37] questions whether economic evalu-
ation play an important role in the Dutch system as actual cases (e.g. orphan drugs for 
Pompe and Fabry disease) [6] showed that it seems rather di cult to put restrictions 
even though the economic evidence is clear. his situation might prove diferent in the 
near future as ZIN is in the process of further optimizing the current (appraisal) system, 
by further operationalizing the criteria necessity and cost-efectiveness, as well as using 
deliberative processes based on Daniels and Sabin’s Accountability for Reasonableness 
framework [38].
HTA in Germany
Germany was relatively late compared to other European countries to engaging in HTA 
activities [39]. In the early years, HTA was mainly conducted by individual researchers. 
HTA has now become an oicial necessity in decision-making with regard to which health 
technology should be covered through SHIs (Statutory Health Insurance), as a result of the 
SHI Modernization Act, which was announced in 2014 [39,40].
Currently, the main organizations involved in HTA are IQWiG (Institute for Quality 
and Eiciency in Health Care or Institut für Qualität und Wirtschaftlichkeit im Gesundheits-
wesen in German) for assessment and G-BA (Federal Joint Committee or Gemeinsamer 
Bundesausschuss in German) for the appraisal [39,40]. he G-BA has a department which 
can provide scientiic advice for assessment, but they almost never produce HTA reports.
he G-BA is a multisectoral committee, which consists of dentists, physicians and rep-
resentatives of hospitals, (non-voting) patients and SHIs [40]. It has a responsibility to 
control coverage and limitations on prescribing in order to ensure eiciency in the sys-
tem [40]. herefore, it evaluates new examination and treatment methods, assesses new 
medicines, categorizes them into reference price groups and publishes clinical guidelines, 
which need to be presented to the Federal Ministry of Health for approval [40]. he G-BA 
decisions based on the level of additional beneit may be appealed based on evidence 
and legislation [40]. Additional beneit is determined by assessing mortality, morbidity 
and health related quality of life of the new medicine versus current standards, similar 
to France [41]. he G-BA makes the inal decision publicly available. Most HTAs are con-
ducted by IQWiG.
IQWiG is an independent institute, which was founded in 2004, to assess medical ei-
ciency, quality and efectiveness [40]. Since the new Competition Enhancement Act was 
announced in 2008, formal cost-efectiveness analyses have become an indispensable 
part of the German system and IQWiG is authorized to assess cost-beneit ratios of med-
icines in Germany [40]. It prepares HTA reports either at G-BA requests or self-initialized 
(for non-pharmaceutical products) [40]. It does not have any decision-making powers 
and its advice to the G-BA (e.g. including or excluding health technologies into the SHI 
coverage) are not binding [39,40]. he most important criteria used in the assessment 
phase are patient relevant outcomes, including mortality, morbidity and health related 
quality of life as opposed to surrogate measures. Context and implementation issues are 
partly taken into account (e.g. prescribing restrictions for certain pharmaceutical prod-
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ucts are investigated). IQWiG is forced by law to make the evidence report of the assess-
ment publicly available [31]. IQWiG has an informal collaboration with HAS (French Na-
tional Health Authority) and NICE (National Institute for Health and Care Excellence), 
which provides bilateral sharing of basic information and scientiic evidence with France 
and the England (in the United Kingdom) [40].
HTA in England/Wales, UK (United Kingdom)
HTA processes are usually aimed to evaluate value for money and eventually inform 
health policy-making at the national level in the UK [42]. NICE (National Institute for 
Health and Care Excellence), which is an independent public body founded as a Special 
Health Authority in 1999, is the main organization which is responsible for providing na-
tional guidance on the promotion of good health and the prevention and treatment of ill 
health [42]. herefore, it supplies national guidance on speciic health technologies (e.g. 
drugs and medical devices) through its HTA processes and on clinical practice through its 
clinical guideline development processes based on existing evidence [42,43]. However, 
in course of time after its foundation, it has taken up further duties in the ield of pub-
lic health as well [42].
Purchasers in the UK have local freedom to choose which health technologies they 
will buy and they are not obliged to purchase only cost-efective health technologies [43]. 
In other words health technologies, which are not found cost-efective, may also be cov-
ered locally [43]. he NHS (National Health Service) organizations in England and Wales 
are obliged to inance drugs and therapies approved by NICE based on HTA reports since 
2002 [42]. It is also an obligation for NHS organizations to revise their clinical manage-
ment procedures when NICE clinical guidelines are published [42].
NICE is responsible with both the assessment and the appraisal. Once a technology 
is referred to NICE for evaluation, NICE writes a draft assessment report together with 
the Department of Health, including health outcomes and costs. After stakeholder con-
sultations, the scope of the HTA is inalized and all consultees and others are invited to 
make a submission. he evidence provided by the manufacturer is then reviewed by an 
independent academic group [31]. he Appraisal Committee of NICE comprises of 20-
25 members from diverse backgrounds and includes lay members. It is the Committee’s 
role to appraise the evidence gathered in the assessment phase, including clinical efec-
tiveness and health-related factors, cost-efectiveness, social value judgements and costs 
(savings) outside NHS or non-health gains. Additional criteria are taken into account for 
end of life medicines. he Committee summarizes the key evidence and their own view 
on the evidence, and provides a preliminary recommendation, which is open for consul-
tation. Comments are considered in a second Appraisal Committee meeting, after which 
the inal recommendation to the NHS follows.
here is evidence showing that NICE guidance may afect the market share of drugs, 
patient access to medicines, prescription attitudes and clinical practices [42]. Most of the 
drugs, which exist on the market of the UK, are assessed and relevant guidance is pub-
lished by NICE [43]. Additionally, Northern Ireland, Scotland and Wales have their own 
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advisory organizations to provide recommendations about clinical efectiveness, cost-ef-
fectiveness and prescription of medicines with health care devolved in the United King-
dom [43]. SMC (Scottish Medicines Consortium) takes this responsibility in Scotland, 
while AWMSG (All Wales Medicines Strategy Group) does it in Wales. NHS boards in 
Scotland should act in line with SMC recommendations [43]; however, this may not al-
ways be possible in view of budgetary issues.
Comparison on HTA and Decision Outcomes in Different Settings
As described above, the way in which HTA bodies/programmes are organized and pro-
vide input to decision making difers between health systems. In some countries, the 
HTA body (e.g. NICE in the UK) or an advisory council (e.g. National Health Care Insti-
tute in the Netherlands) develops guidance and/or recommendations concerning reim-
bursement of health technology. In other countries, there is a strong separation between 
the assessment and appraisal procedure (e.g. in Germany, IQWiG provides the assess-
ment and the national authority – G-BA, decides on the added beneit of pharmaceutical 
products). Other models also exist – e.g. in France, where HAS (Haute Autorité de Santé) 
is mainly responsible for providing recommendations regarding the reimbursement of 
pharmaceuticals. he CEPS (Comité Économique des Produits de Santé), also a separate 
body, is responsible for price negotiations with pharmaceutical companies.
Abbreviated 
indication
Brand name 
(generic)
HTA recommendation
Germany
The 
Netherlands
France
England/
Wales
Scotland Poland
Breast 
cancer
Eribulin Equal 
EHQHÀW
Added 
EHQHÀW
Added 
EHQHÀW
Negative Negative Negative
Colorectal 
cancer
$ÁLEHUFHSW Added 
EHQHÀW
Not 
assessed
Equal 
EHQHÀW
Negative Negative Positive
Gastric 
cancer
Tegafur/ 
Gimeracil/ 
Oteracil
Not 
assessed
Lesser 
EHQHÀW
Lesser 
EHQHÀW
Not 
assessed
Positive Negative
Melanoma Ipilimumab Added 
EHQHÀW
Added 
EHQHÀW
Added 
EHQHÀW
Positive Negative Positive
Non-small 
cell lung 
cancer
Crizotinib Equal 
EHQHÀW
Not 
assessed
Added 
EHQHÀW
Negative Negative Negative
Prostate 
cancer
Abiraterone Added 
EHQHÀW
Equal 
EHQHÀW
Added 
EHQHÀW
Positive Negative Positive
Renal cell 
carcinoma
Axitinib Added 
EHQHÀW
Not 
assessed
Added 
EHQHÀW
Positive Negative Positive
Table 1. Recommendation regarding (selected) oncology drugs having received 
marketing authorization (2011-2013) in selected EU countries [27,47]
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With regard to the use of HTA in decision making, it can be observed that in addition 
to the level of clinical beneit and cost-efectiveness, increasingly other aspects are tak-
en into account in the appraisal [44]. For orphan drugs diferent criteria might apply in 
either the assessment phase (e.g. France), the appraisal phase (e.g. he Netherlands) or 
both (e.g. Germany) [45]. he approach taken seems to be correlated with the institution-
al context and the organization making the recommendation or decision, the inancing 
and governance of the health system, as well as the culture and values of a country [46]. 
Obviously, this might lead to diferent decisions. his can also be seen in the Table 1, in 
which selected countries used the same assessment results based on relative efective-
ness (using EUnetHTA Core Model). he diverging results could also be due to the fact 
that the scope (comparators and cost considerations) and the methodology used vary 
across countries [47]. Allen et al [48] found similar results in a study on national reim-
bursement decisions in nine countries for more than 100 new active substances approved 
by the European Medicines Agency.
15.6 Ongoing Developments Impacting on the Role of HTA 
to Improve the Managed Entry of New Medicines
here have been particular issues with the funding of new medicines for Hepatitis 
C given the potential number of patients, the possibility of a cure for this chronic in-
fectious disease, the high launch price in a number of countries with associated poten-
tial budget impact, as well as concerns with the high level of proitability in some coun-
tries at over 99.9% gross proit at the initial requested prices [49-51]. his has resulted 
in extensive negotiations for discounts as well as restricted use, including managed en-
try agreements, which is not in the best interests of patients or health authorities [50-
54]. here have also been concerns and issues with increasing prices of new cancer med-
icines and those for orphan disease despite little evidence that new cancer medicines 
extend or improve life [4,5,55,57]. he cost of new medicines to treat patients with can-
cer have risen more than tenfold in the past decade despite the low cost of goods of some 
new cancer medicines, lower than publicized R&D costs as well as current levels of prof-
itability [58-61]. High reimbursed prices for new cancer medicines has been helped by 
the emotive nature of the disease area, which has typically translated into greater leeway 
among payers for granting premium prices even for very modest improvements in pa-
tient outcomes [4-6,55,57,61-63]. hese concerns have already resulted in requests for 
price moderation for new cancer medicines for future sustainability [61,64,65]. Health 
authorities, particularly those providing universal access, are increasingly concerned if 
prices continue to rise given the appreciable number of new cancer medicines in devel-
opment [4,5,65-67]. A similar situation is also seen for new medicines for orphan diseas-
es given ever increasing prices [4,5,68], with public pressure resulting in, for instance, 
new medicines for orphan diseases in the Netherlands funded up to 15 million Euros/
QALY [69].
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Having said this, independent drug information journals, particularly in Europe, be-
lieve very few new medicines are truly innovative; with the vast majority seen as similar 
in their impact on health, or only marginally better, than existing medicines [5,6,70,71]. 
Consequently, these new medicines should command lower or similar prices to existing 
standards; or at best only limited increases versus existing standards based on HTA as 
well as key pricing and reimbursement considerations [4,5,21,41,72]. However, currently 
concerns with the deinition of innovation and value, as well as issues of priority, unmet 
need and emotion, cloud such discussions and deliberations [63,73-76]. his is a chal-
lenge for the future especially in Europe to maintain the ideals of equitable and compre-
hensive healthcare.
here have also been concerns with some of the marketing activities of pharmaceuti-
cal, especially if this leads to inappropriate prescribing which add to costs and/ or poten-
tial patient safety [3,77-83]. his includes issues of ‘evergreening’ of medicines further 
adding to costs without necessarily improving patient care [84]. However, there are on-
going moves to address key stakeholder concerns particularly regarding the promotion 
of new medicines [85-87]. his includes improving the core competencies and standards 
of pharmaceutical physicians [88,89]. In addition, educating physicians that patients en-
rolled into clinical trials may be diferent to those seen in routine clinical care, which can 
mean additional vigilance [3,90].
here are also concerns among some health authorities regarding risk sharing arrange-
ments, or Managed Entry Agreements (MEAs), to improve the afordability of new med-
icines and reduce uncertainty [25]. hese have to be balanced though against no reim-
bursement if no agreements are reached. hese concerns include potential savings in 
reality, whether health systems have the ability to monitor patient outcomes in routine 
clinical practice, and the administrative burden and costs associated with such schemes 
[3,25,75,91-93]. However not surprisingly given rising prices for new medicines, the 
number of such arrangements has grown in recent years especially for new anti-cancer 
medicines, although this is not universal [4,25,94-96]. It is likely these schemes will con-
tinue, certainly in the short to medium term, given increasing inancial pressures and 
limited alternatives [96,97]. However, this has to be balanced with the need for health au-
thorities and pharmaceutical companies to publish the outcomes of such schemes against 
their objectives to guide future decision making. Currently, there is a paucity of such in-
formation [4,25].
Alongside this, there are also increasing concerns among payers across Europe regard-
ing issues relating to the potential introduction of adaptive pathways for new medicines 
to accelerate access to new innovative medicines [98,99]. Key concerns include i) issues of 
payment, i.e. who will pay for the new medicine during its testing phase among patients 
and at what price, ii) where does the product liability lie prior to full marketing autho-
rization, pricing and reimbursement, iii) how is innovation and unmet need deined, iv) 
how long are new medicines in the adaptive pathways process prior to full evaluation, v) 
whether such schemes are needed in reality with fast-track schemes for new medicines al-
ready in existence, vi) whether health authorities currently have the necessary ability to 
monitor the efectiveness and safety of new medicines in routine clinical care, vii) wheth-
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Pre-launch activities
 +RUL]RQVFDQQLQJ
 3RWHQWLDOEXGJHWLPSDFWRIQHZPHGLFLQHVEDVHGRQ
DVVHVVPHQWRISRWHQWLDOKHDOWKJDLQDQGOLNHO\SULFHYHUVXV
FXUUHQWVWDQGDUGV
 3RWHQWLDOFDQGLGDWHIRU$3²LPSOLFDWLRQVIRUHDUO\
DVVHVVPHQWRIYDOXH3	5DQGSDWLHQWUHJLVWULHV
 'HYHORSWUHDWPHQWJXLGHOLQHV$3RUVWDUWGHYHORSLQJ
WKHPLQFOXGLQJSRWHQWLDO4,VXVLQJUREXVWSULQFLSOHV
 ,QVWLJDWLRQRIGLDORJXHZLWKDOONH\VWDNHKROGHUVJURXSV
Peri-launch activities
 3	5QHJRWLDWLRQVIRUQHZPHGLFLQHVRUUHQHJRWLDWLRQVIRU
QHZ$3PHGLFLQHV
 (YDOXDWHSURSRVHG0($VLQFOXGLQJSURSRVHVRXWFRPH
EDVHGVFKHPHVDVZHOODVSURSRVHGSULFHVWRVWD\ZLWKLQ
EXGJHWV
 ,ISHUWLQHQWILQDOL]HSDWLHQWUHJLVWULHVDQ\4,VDVZHOODV
WUHDWPHQWJXLGDQFHIRUQHZPHGLFLQHV
 6WDUWFRPPXQLFDWLRQSURJUDPPHVZLWKDOONH\VWDNHKROGHU
JURXSV
Post-launch activities
 )XUWKHUIROORZXSRIWKHHIIHFWLYHQHVVDQGVDIHW\RIQHZ
PHGLFLQHVLQURXWLQHFDUH$3RULQVWLJDWHIROORZXS
WKURXJKHOHFWURQLFKHDOWKUHFRUGVUHJLVWULHV
 $VVHVVSUHVFULELQJDJDLQVWDJUHHG
JXLGDQFH4,VSUHVFULELQJUHVWULFWLRQV
 $VVHVVZKHWKHUDJUHHG0($VDUHDFKLHYLQJDJUHHG
REMHFWLYHVLQVWLJDWHDFWLYLWLHVZKHUHFRQFHUQV
 'HYHORSDGGLWLRQDOPHDVXUHVLIQHHGHGLIXWLOL]DWLRQDQG
H[SHQGLWXUHRXWVLGHDJUHHGOLPLWV
(YLGHQFHJHQHUDWLRQZLWKLPSOLFDWLRQVIRUSULFLQJ
IXQGLQJDQGXWLOL]DWLRQRIQHZPHGLFLQHV
3URSRVHGDGDSWLYHSDWKZD\V
IRUDJUHHGQHZPHGLFLQHV
Figure 1. Schematic representation of ongoing models across Europe to improve the 
PDQDJHGHQWU\RIQHZPHGLFLQHV0RGLÀHGIURP>@
AP = Adaptive Pathways; MEAs = Managed Entry Agreements; P&R = Pricing and Reimbursement; 
QIs = Quality Indicators
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er payers have the necessary powers to disinvest in new medicines if found not to be cost-
efective in reality and manufacturers are reluctant to lower prices. Additionaly, if health 
authorities do not have the necessary IT systems, who would pay for their subsequent de-
velopment [99]? However, the use of patient registries post launch have helped address 
issues of appropriateness and concerns with new medicines such as potentially increas-
ing rates of infection and cancer with the use of biological medicines to treat immunolog-
ical diseases such as rheumatoid arthritis and psoriasis. Such concerns have not proved 
to be the case in long term follow-up of these patients [100-106]. Long term follow-up 
of patients in public healthcare databases have also demonstrated signiicantly improved 
long-term graft survival in kidney transplant patients prescribed cyclosporine versus ta-
crolimus despite current beliefs [107].
hese issues and concerns have resulted in the development of new models, especially 
among European countries, to better manage the entry of new medicines, which also in-
cludes potential new models for valuing new medicines for orphan diseases given current 
concerns [3-6,66,108]. he proposed models include the role of HTA. In addition, HTA 
activities are increasingly used to guide disinvestment activities, with monies transferred 
to fund more efective and/or more eicient medicines [18-20]. Discussion of disinvest-
ment activities is outside the scope of this chapter. However as mentioned, there have 
been published case histories regarding the disinvestment of medicines from a number 
of countries [18]. More recently, the authorities in Brazil have published a new approach 
that also includes assessing the efectiveness and safety of potential medicines for disin-
vestment in the real world, adding robustness to any decisions [19].
New Models to Improve the Managed Entry of New Medicines
A three-stage model has been proposed, and is now being implemented, to improve 
the managed entry of new medicines especially from a health authority perspective [3-
6,66,108,109] (Figure 1). he model begins with pre-launch activities including horizon 
scanning and forecasting, the potential development of quality indicators for new med-
icines, as well as including new medicines that could go through the proposed adaptive 
pathways program especially in Europe [98,109-111]. his will increasingly include in Eu-
rope potential new medicines going through the adaptive pathways scheme [98,99].
Peri-launch activities including a fuller assessment of the potential value, requested 
prices and likely reimbursement, with or without a managed entry agreement, of new 
medicines versus any preliminary evaluation pre-launch [5,21,66,94]. Post-launch activi-
ties include the evaluation of ongoing managed entry agreements including continuing 
assessment of the efectiveness and safety of new medicines in routine clinical practice as 
well as the monitoring of prescribing against agreed quality indicators and guidelines.
Pre-launch activities
Pre-launch activities include horizon scanning and budgeting activities [109]. Horizon 
scanning is seen and deined as «identifying new medicines or new uses of existing med-
icines that are expected to receive marketing authorization from the Regulatory Author-
 +RUL]RQVFDQQLQJ
 3RWHQWLDOEXGJHWLPSDFWRIQHZPHGLFLQHVEDVHGRQ
DVVHVVPHQWRISRWHQWLDOKHDOWKJDLQDQGOLNHO\SULFHYHUVXV
FXUUHQWVWDQGDUGV
 3RWHQWLDOFDQGLGDWHIRU$3²LPSOLFDWLRQVIRUHDUO\
DVVHVVPHQWRIYDOXH3	5DQGSDWLHQWUHJLVWULHV
 'HYHORSWUHDWPHQWJXLGHOLQHV$3RUVWDUWGHYHORSLQJ
WKHPLQFOXGLQJSRWHQWLDO4,VXVLQJUREXVWSULQFLSOHV
 ,QVWLJDWLRQRIGLDORJXHZLWKDOONH\VWDNHKROGHUVJURXSV
 3	5QHJRWLDWLRQVIRUQHZPHGLFLQHVRUUHQHJRWLDWLRQVIRU
QHZ$3PHGLFLQHV
 (YDOXDWHSURSRVHG0($VLQFOXGLQJSURSRVHVRXWFRPH
EDVHGVFKHPHVDVZHOODVSURSRVHGSULFHVWRVWD\ZLWKLQ
EXGJHWV
 ,ISHUWLQHQWILQDOL]HSDWLHQWUHJLVWULHVDQ\4,VDVZHOODV
WUHDWPHQWJXLGDQFHIRUQHZPHGLFLQHV
 6WDUWFRPPXQLFDWLRQSURJUDPPHVZLWKDOONH\VWDNHKROGHU
JURXSV
 )XUWKHUIROORZXSRIWKHHIIHFWLYHQHVVDQGVDIHW\RIQHZ
PHGLFLQHVLQURXWLQHFDUH$3RULQVWLJDWHIROORZXS
WKURXJKHOHFWURQLFKHDOWKUHFRUGVUHJLVWULHV
 $VVHVVSUHVFULELQJDJDLQVWDJUHHG
JXLGDQFH4,VSUHVFULELQJUHVWULFWLRQV
 $VVHVVZKHWKHUDJUHHG0($VDUHDFKLHYLQJDJUHHG
REMHFWLYHVLQVWLJDWHDFWLYLWLHVZKHUHFRQFHUQV
 'HYHORSDGGLWLRQDOPHDVXUHVLIQHHGHGLIXWLOL]DWLRQDQG
H[SHQGLWXUHRXWVLGHDJUHHGOLPLWV
(YLGHQFHJHQHUDWLRQZLWKLPSOLFDWLRQVIRUSULFLQJ
IXQGLQJDQGXWLOL]DWLRQRIQHZPHGLFLQHV
3URSRVHGDGDSWLYHSDWKZD\V
IRUDJUHHGQHZPHGLFLQHV
PDQDJHGHQWU\RIQHZPHGLFLQHV0RGLÀHGIURP>@
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ity in the near future and estimating their potential impact on patient care» [113-116]. 
Since 1999, 18 countries across continents including Europe have been collaborating un-
der the EuroScan project [111,116-118]. Each member agency is unique in its approach; 
however, they all have a common goal of informing particularly health authorities and 
hospital managers about new and emerging technologies that could have a signiicant im-
pact on their health system [104,117,119,120]. Typical activities regarding horizon scan-
ning among leading Western countries, including leading Western European countries, 
are discussed in Figure 2.
Key iltration and information components of reports in European countries including 
Austria, Italy, Sweden and the UK are contained in Table 2.
Horizon scanning units can issue diferent reports as new medicines approach po-
tential marketing authorization to further help heath authorities in their planning 
[109,111]. his includes Italy (Table 3), with medicines selected based on an agreed iltra-
tion process (Table 2).
,GHQWLI\QHZPHGLFLQHVDQGILOWHULQJ²LQFOXGLQJ
SRSXODWLRQVL]HSRWHQWLDOWRDGGWRFXUUHQWWUHDWPHQW
DQGSRWHQWLDOVLGHHIIHFWV
Step 1
3ULRULW\VHWWLQJIRUWRSLFVPHGLFLQHVLQFOXGLQJOHYHORI
XQPHWQHHGDELOLW\RIQHZPHGLFLQHVWRDGGUHVVWKLV
DQGOLNHO\EXGJHWLPSDFW
Step 2
(DUO\DVVHVVPHQWRIWKHSRWHQWLDOUROHDQGYDOXH
RIQHZPHGLFLQHVLQFOXGLQJILQGLQJVIURPDQ\SKDVH
,,RU,,,VWXGLHV
Step 3
'LVVHPLQDWHXQELDVHGILQGLQJVWRNH\VWDNHKROGHU
JURXSVLQFOXGLQJSD\HUVDQGEXGJHWKROGLQJ
SK\VLFLDQV
Step 4
0RQLWRULQJWKHXVHIXOQHVVRILQIRUPDWLRQSURYLGHG
HVSHFLDOO\DPRQJSD\HUV²LQFOXGLQJIHHGEDFN
DQGDQ\VXJJHVWLRQVIRUWKHIXWXUH
Step 5
Figure 2. +RUL]RQVFDQQLQJVHTXHQFLQJDFWLYLWLHV0RGLÀHGIURP>@
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Enhancing the robustness forecasts concerning the likely utilization and expendi-
ture of new medicines is increasingly essential to improve subsequent planning and re-
source allocation given ever increasing pressure on resources [3,4]. One example combin-
ing a number of factors to improve budget forecasting, which involves multiple expert 
groups, is from Stockholm County Council in Sweden [110]. heir forecast with expert 
groups, including physicians, pharmacists and health authority personnel, involves as-
sessing the likely role of new medicines as well as the future utilization of existing med-
icines. Regression analyses are conducted on aggregate sales data and predicted trends 
are adjusted for possible changes in the market including possible patent expiries, with 
implications for appreciably lowering the price of medicines, as well as potential chang-
,GHQWLI\QHZPHGLFLQHVDQGILOWHULQJ²LQFOXGLQJ
SRSXODWLRQVL]HSRWHQWLDOWRDGGWRFXUUHQWWUHDWPHQW
DQGSRWHQWLDOVLGHHIIHFWV
3ULRULW\VHWWLQJIRUWRSLFVPHGLFLQHVLQFOXGLQJOHYHORI
XQPHWQHHGDELOLW\RIQHZPHGLFLQHVWRDGGUHVVWKLV
DQGOLNHO\EXGJHWLPSDFW
(DUO\DVVHVVPHQWRIWKHSRWHQWLDOUROHDQGYDOXH
RIQHZPHGLFLQHVLQFOXGLQJILQGLQJVIURPDQ\SKDVH
,,RU,,,VWXGLHV
'LVVHPLQDWHXQELDVHGILQGLQJVWRNH\VWDNHKROGHU
JURXSVLQFOXGLQJSD\HUVDQGEXGJHWKROGLQJ
SK\VLFLDQV
0RQLWRULQJWKHXVHIXOQHVVRILQIRUPDWLRQSURYLGHG
HVSHFLDOO\DPRQJSD\HUV²LQFOXGLQJIHHGEDFN
DQGDQ\VXJJHVWLRQVIRUWKHIXWXUH
+RUL]RQVFDQQLQJVHTXHQFLQJDFWLYLWLHV0RGLÀHGIURP>@
Criteria Key considerations
Filtration Criteria  Current status, e.g. how close to marketing authorization
 Likely population size
 Severity of the disease area in question/whether a current 
priority area
 Ability to meaningfully improve patient outcomes/address 
a situation currently associated with appreciable morbidity 
DQGPRUWDOLW\²FRQVHTXHQWO\SRWHQWLDOO\LQÁXHQFHWUHDWPHQW
guidelines
 Potentially innovative way of treating current diseases/level of 
innovation
 Possibility of safety concerns, e.g. dabigatran
 Potential budget impact including the potential for savings; part 
of a new growing class of medicines
 Potential for off-label use
 Could potentially require reorganization of healthcare services
 Likely media/public interest
 Likely non-optimal introduction rate following marketing 
authorization
 Potentially legal, ethical or politically interesting considerations
Key components 
of early 
assessment 
reports
 Description of the medicine including disease area and mode 
of action
 Likely clinical need and size of the likely patient population(s)
 Current treatment approaches and alternatives; and possible 
pipeline products
 6XPPDU\RIHIÀFDF\LQ3KDVH,,DQG,,,VWXGLHVGHSHQGLQJRQ
availability and timing of the reports)
 Current completed and ongoing studies
 Likely budget impact as well as any early pharmacoeconomic 
assessment
 Potential to monitor utilization post-launch against agreed 
guidance
 Possible marketing approaches among companies
Table 2. .H\ÀOWUDWLRQFULWHULDDQGFRPSRQHQWVRIKRUL]RQVFDQQLQJUHSRUWVLQ(XURSH
0RGLÀHGIURP>@
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es in the reimbursement status of medicines [109,110,122]. All of these factors are com-
bined into a yearly forecast, which is subsequently monitored to improve future forecast-
ing [109,110,118].
hese activities in Europe will grow with the potential introduction of new medicines 
under the adaptive pathways scheme [98]. Similarly, for any early access schemes where 
budgetary responsibility is borne by the payers rather than pharmaceutical companies. 
hese potentially include conditional approval schemes to accelerate access to new med-
icines for serious debilitating or life-threatening conditions; however, there are concerns 
[123,124]. his is diferent to fast track schemes, which are already in existence [98].
Whilst proposed adaptive pathways are welcomed by European payers and their advisers 
to accelerate early access of new medicines, especially those for debilitating diseases and 
where currently limited or no therapies are available for treatment, there are still consider-
able concerns. hese concerns have been summarized in a number of published papers 
[98,99,123,125,126], and include the fact that there will still be inequity in the availability 
of new medicines across Europe depending on potential prices. Payer HTA considerations 
for assessing potential prices for new medicines going through the adaptive pathways route 
will also need to evolve to consider how to efectively deal with increased uncertainty, and 
build this into their negotiations with pharmaceutical companies [99,127].
Peri-launch activities
As already mentioned in previous paragraphs, European countries typically adopt dif-
ferent approaches to the pricing and reimbursement of new medicines, which can poten-
Reports available 36 
months before potential 
MA for selected medicines
Reports 18 months before 
potential MA for selected 
medicines
Report 12 months before 
potential MA for selected 
medicines
The report provides data 
from Phase II trials as well as 
of ongoing Phase III trials of 
targeted medicines.
These reports help 
identify areas of 
research of interest to 
the Italian NHS which 
are currently not being 
met by pharmaceutical 
companies.
These reports are essentially 
for internal purposes 
among regional health 
authorities in Italy.
The reports critically 
assess available results of 
completed Phase III trials 
and their implications.
They help identify and 
prioritize emerging 
medicines likely to have 
a clinical and economic 
impact on the Italian NHS.
These reports critically 
evaluate available 
HIÀFDF\DQGVDIHW\GDWD
on new agreed medicines.
The Italian Unit assesses 
their possible level of 
innovation, possible 
place in therapy (target 
population) as well as 
the potential economic 
(budget) and social 
impact.
The reports are seen as 
particularly useful for 
national and regional 
health authorities.
Table 3. Different reports and their timescales from the Italian Horizon Scanning Project 
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tially be classiied into those countries that assess the level of innovation of new medi-
cines against existing standards using HTA principles as part of price negotiations such 
as Austria, France and Germany [4,5,21,128]. Alternatively, basing reimbursement and 
funding decisions on economic criteria such as cost/QALY with or without threshold lev-
els [4,5,21,129,130]. Currently, only a minority of countries using economic principles 
set threshold levels [21]; with suggestions by some that threshold levels should be low-
ered for long term sustainability [131].
European health authorities are increasingly requesting Budget Impact Analyses (BIA) 
as part of health economic assessments for reimbursement/funding and formulary ap-
proval decisions [4,109]. his will help with future forecasting, building on current initia-
tives [109,110] as BIAs help estimate the possible inancial consequences with the envis-
aged difusion of new technologies into healthcare systems [132]. Key components of any 
budget impact analyses include [109,133]:
t he perspective of the budget holder/payer.
t he deined time horizon (which is typically up to 3 years).
t Clearly deining the setting.
t Expressing the results as undiscounted cost diferences between the use of the new 
medicines and the current situation.
t Taking into account potential trade-ofs in terms of healthcare resources taking ac-
count of the potential variable efectiveness of the new medicine in diferent popula-
tions, especially if there are likely to be diferences in the patient populations in rou-
tine clinical care compared with the Phase III trials.
here are concerns though with the majority of published BIAs including issues of 
bias, which negatively impacts on their current usefulness to health authorities [134].
Peri-launch activities also increasingly include assessing possible managed entry 
agreements (MEAs), sometimes referred to as risk sharing arrangements or other dei-
nitions [25,91,94,95], especially in Europe. However as mentioned, there are increasing 
concerns with such schemes, whether inancial based or outcome based, among health 
authority personnel [25,91,109]. A key consideration, especially for outcome based 
schemes, is the availability of IT systems to routinely collect data on the use, efective-
ness and safety of new medicines as part of these schemes. he use of individual patient 
records or registries for each new medicine, as well as any paper based scheme, quick-
ly becomes challenging for clinicians and other healthcare professionals [91]. Howev-
er, these concerns have to be weighed against the potential beneits of MEAs including 
[91,94,109]:
t Improving the opportunity for reimbursement, especially if decision making in-
cludes economic considerations such as cost/QALY and/or strict pricing criteria for 
new medicines, and for ‘payers’ to work within deined budgets.
t Such schemes help limit the ‘of label’ use of new medicines and/ or indication creep 
in clinical practice.
t Potential for payers to only fund new medicines that produce the desired health gain 
and/or help target physician prescribing to those patients where health gain is great-
est through for instance biomarkers and other strategies.
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t Enhance the ability of health authorities to monitor the safety and efectiveness of 
new treatments in routine clinical practice, especially where patients may be more el-
derly and/or more co-morbid than those enrolled into Phase III clinical trials.
In addition, with respect to ultra-orphan medicines, given the complexities of R&D, 
conditional approval and reimbursement including managed entry schemes may be one 
way forward to enhance their reimbursement and funding [135]. However, a prerequisite 
should be the demonstration of a minimum signiicant clinical beneit within a reason-
able time frame, with limited reliance on any surrogate measures [135].
Consequently, there is an urgent need for publications assessing the impact and use-
fulness of MEAs against agreed criteria to provide future direction.
here are also concerns with current approaches to the pricing of cancer medicines and 
those for orphan diseases leading to proposed changes. hese are summarized in Sections 
“New Cancer Medicines” and “New Medicines for Orphan Diseases” below. New propos-
als are also being considered for gene therapies given their likely costs, which include an-
nuity payments [136,137]. Debates regarding the funding of new gene therapies will con-
tinue as more are launched.
New cancer medicines
Concerns with increasing prices of new cancer medicines, the limited health gain of 
an appreciable number of them including potential ‘targeted treatments’, and the num-
ber in development [4,5,55,57,61,62,138], have resulted in suggestions for establishing 
minimum targets for stating whether new cancer medicines are an advance, or not, for 
pricing and funding justiications [139,140]. As a result, potentially address concerns 
that funding of new cancer medicines at high prices, with often limited health gain, has 
been enhanced by the emotive nature of the disease [63,141]. As a result, negatively im-
pacting on available resources for other patient populations within inite budgets. Sim-
ilar considerations exist where speciic budgets have been assigned to new cancer med-
icines to the detriment of other disease areas [142]. However, such concerns with the 
potential impact on raising the bar for licensing and funding considerations are not uni-
versal [143,144].
Suggestions for advanced cancers center on minimum increases in additional survival, 
especially given concerns with surrogate markers such as progression free survival, and 
overall response, on their impact on overall survival [4,55,139,145-148]. hese debates 
will continue, with HTA analyses playing an increasing role.
Other suggestions to help improve future pricing and reimbursement considerations 
in challenging areas include multi-stakeholder debates to better align the needs for ro-
bust evidence requirements, given concerns with surrogate markers, and a collectively 
shared deinition and acceptance on what are clinically relevant beneits for patients and 
society across disease areas [149]. As a result, help better shape the concepts of value to 
improve pricing and reimbursement deliberations in the future and reduce current con-
troversies. his is particularly important in the cancer area given the appreciable number 
of new cancer medicines in development, and their likely prices, coupled with consider-
able unmet need [5,16,67].
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New medicines for orphan diseases
here is also increasing concern regarding the funding for new orphan medicines giv-
en ever increasing prices [4,5], despite potential ofsets with risk sharing arrangements 
[135]. Such concerns are exacerbated by situations where new medicines for orphan dis-
eases have been funded up to 15 million Euros/QALY the non-classic form of Pompe dis-
ease [69]. However, this is not always the case with ten (over 50%) of 19 orphan drugs 
available on the EMA website in November 2013, for which health economic data were 
available, met a threshold level of 30,000 GB£/QALY [150].
Such deliberations have resulted in the development of multicriteria decision analyses 
tools involving all key stakeholder groups [4-6,151,152]. Examples include the Transpar-
ent Value Framework developed via an EU initiative [6]. It is expected such developments 
will grow given the number of orphan medicines in development, including very target-
ed cancer therapies [67,153].
Post-launch activities
Post launch activities are increasing as payers and others wish to assess the efective-
ness and value of new medicines in routine clinical care, building on examples in for in-
stance France. his includes any assessment as part of adaptive pathways programmes 
or MEAs.
As mentioned, this has included assessing rates of infection and cancer with the use 
of biological medicines to treat immunological diseases such as rheumatoid arthritis and 
psoriasis [100-106], as well as assessing long-term graft survival in kidney transplant pa-
tients prescribed either cyclosporine or tacrolimus [107]. Other examples including as-
sessing the appropriateness of prescribing, as well as the efectiveness and safety of new 
oral anti-coagulants such as dabigatran given early concerns [3,154-156] as well as the 
use and potential risks associated with medicines for weight loss [157]. Post launch ac-
tivities also include risk management plans, which incorporate risk evaluation and mit-
igation strategies normally required by the EMA and FDA as part of any medicine ap-
proval process to help ensure that the beneits of any new medicine outweighs its risks 
[158,159].
Conclusion and Next Steps
It is likely that the managed entry of new medicines will become more formalized with 
increasing horizon scanning and budget activities before launch, especially with develop-
ments such as adaptive pathways. his will require an increasing role for HTA and the de-
velopment of additional skills dealing with increasing uncertainty.
It is also likely that we will see developments in reimbursement decision making es-
pecially for new cancer medicines and those for orphan diseases, as well as new gene 
therapies. his is essential given their potential budget impact and continuing concern 
with available resources coupled with continuing unmet need. All key stakeholder groups 
should be part of such developments in the future.
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